| Abstract |
Objective To explore pneumoconiosis combined with chronic obstructive pulmonary disease (chronic obstructive The study aimed to investigate the effects of rock salt aerosol therapy on the symptoms, lung function, blood gas analysis, and airway inflammation in patients with pulmonary diseases, particularly COPD, after routine treatment. Methods A total of 114 patients with pneumoconiosis combined with chronic obstructive pulmonary disease were collected from the Third Peoples Hospital of Xinjiang Uygur Autonomous Region between January and December 2021. Using a random number table, the patients were divided into an observation group and a control group, each consisting of 57 patients. Before treatment, both groups underwent mMRC scoring, lung function assessment, blood gas analysis, and tests for inflammatory markers such as interleukin IL-6 and tumor necrosis factor TNF-α. Both groups received routine oxygen therapy, anti-infection treatment, and bronchodilator therapy. The observation group also received rock salt aerosol therapy, with a frequency of 1 hour per day, 15 days as one cycle, for six consecutive cycles. Before and after treatment, the mMRC scores, lung function, and blood gas analysis were measured for both groups, and the patients airway inflammation index and side effects were observed. Results After treatment, the symptom scores of both groups were significantly better than before treatment, with statistically significant differences (P<0.05). After treatment, the first-second forced expiratory volume (FEV1), forced vital capacity (FVC), FEV1/FVC, blood oxygen saturation (SPO2), and partial pressure of oxygen (PaO2) levels in both groups increased significantly (P<0.05), while the levels of IL-6 and TNF-α decreased significantly (P<0.05). The FEV1, FVC, FEV1/FVC levels, and SPO2, PaO2 levels in the observation group were all higher than those in the control group (P<0.05); the serum levels of TNF-α and IL-6 were significantly reduced (P<0.05). Both groups experienced mild adverse reactions during treatment, with the incidence rates being 7.02% (4/57) in the observation group and 8.77% (5/57) in the control group, respectively. There was no statistically significant difference between the two groups (P>0.05). Conclusion Rock salt aerosol therapy for pneumoconiosis combined with chronic obstructive pulmonary disease can improve patient symptoms, lung function, and blood gas indicators, reduce airway inflammation, and has fewer adverse reactions, demonstrating definite therapeutic effects.
|